

Streptococcus pyogenes Infections (Infectious Disease) - Drugs in Development, 2021

<https://marketpublishers.com/r/S26F31189FF0EN.html>

Date: March 2021

Pages: 34

Price: US\$ 2,000.00 (Single User License)

ID: S26F31189FF0EN

Abstracts

Streptococcus pyogenes Infections (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections - Drugs in Development, 2021, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape.

Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant pain, swelling, and redness of infected area, fever, dizziness, difficulty breathing, dangerously low blood pressure, and a weak, rapid pulse. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcus pyogenes Infections - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews

of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in IND/CTA Filed, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Streptococcus pyogenes Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Streptococcus pyogenes Infections - Overview

Streptococcus pyogenes Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Streptococcus pyogenes Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development

Cadila Pharmaceuticals Ltd

Crestone Inc

Helix BioMedix Inc

Olymvax Biopharmaceuticals Inc

Wellstat Vaccines LLC

Streptococcus pyogenes Infections - Drug Profiles

(mupirocin calcium + neomycin sulfate + HT-61) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRS-0540 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus [serotype A] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

streptococcus pyogenes (30-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes Infections - Dormant Projects

Streptococcus pyogenes Infections - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Streptococcus pyogenes Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Streptococcus pyogenes Infections - Pipeline by Cadila Pharmaceuticals Ltd, 2021
Streptococcus pyogenes Infections - Pipeline by Crestone Inc, 2021
Streptococcus pyogenes Infections - Pipeline by Helix BioMedix Inc, 2021
Streptococcus pyogenes Infections - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines LLC, 2021
Streptococcus pyogenes Infections - Dormant Projects, 2021
Streptococcus pyogenes Infections - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Streptococcus pyogenes Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Streptococcus pyogenes Infections (Infectious Disease) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/S26F31189FF0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S26F31189FF0EN.html>